精准医学|樊嘉:精准医学时代肝细胞癌的系统治疗|专家视角( 八 )


朱洪兵, 曾普华, 郜文辉, 等. 中西医联合MDT模式在肝癌治疗中的探讨[J]. 中医药导报, 2019, 25(22): 21-24, 31.
[43]CHUMA M, UOJIMA H, NUMATA K, et al. Early changes in circulating FGF19 and Ang-2 levels as possible predictive biomarkers of clinical response to lenvatinib therapy in hepatocellular carcinoma[J]. Cancers (Basel), 2020, 12(2): 293.
[44]LEE JJX, CHAN JJ, CHOO SP. Clinical development of c-MET inhibition in hepatocellular carcinoma[J]. Diseases, 2015, 3(4): 306-324.
[45]RIMASSA L, ABBADESSA G, PERSONENI N, et al. Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib[J]. Oncotarget,2016, 7(45): 72622-72633.
[46]JIANG Y, SUN A, ZHAO Y, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma[J]. Nature, 2019, 567(7747): 257-261.
引证本文

推荐阅读